When AstraZeneca PLC was weighing up an offer to acquire Alexion Pharmaceuticals Inc., it certainly helped that its chief financial officer Marc Dunoyer was also an expert in rare diseases.
Dunoyer joined AstraZeneca from GlaxoSmithKline plc in June 2013, when CEO Pascal Soriot said that he "possessed the rare blend of financial, business and science experience," and while it is unusual for the head of finance at to have extensive clinical knowledge, the Frenchman told Scrip in a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?